These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 30740760)

  • 1. Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
    Iacovelli R; Ciccarese C; Fornarini G; Massari F; Bimbatti D; Mosillo C; Rebuzzi SE; Di Nunno V; Grassi M; Fantinel E; Ardizzoni A; Tortora G
    Br J Clin Pharmacol; 2019 Jun; 85(6):1283-1289. PubMed ID: 30740760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
    Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
    Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.
    Narayan V; Keefe S; Haas N; Wang L; Puzanov I; Putt M; Catino A; Fang J; Agarwal N; Hyman D; Smith AM; Finkelman BS; Narayan HK; Ewer S; ElAmm C; Lenihan D; Ky B
    Clin Cancer Res; 2017 Jul; 23(14):3601-3609. PubMed ID: 28196874
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
    Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
    J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular profile of contemporary treatments of renal cell carcinoma: A single-center prospective study.
    Lee K; Lindenfeld L; Echevarria M; Hsu J; Wong FL; Narayan HK; Lau C; Cai L; Pal SK; Armenian SH; Rhee JW
    Int J Cardiol; 2023 Jun; 380():40-46. PubMed ID: 36958393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible Cabozantinib-Induced Cardiomyopathy.
    Alhussein M; Hotte SJ; Leong DP
    Can J Cardiol; 2019 Apr; 35(4):544.e1-544.e2. PubMed ID: 30935646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
    Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
    Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal pro B-type natriuretic peptide levels: correlation with echocardiographically determined left ventricular diastolic function in an ambulatory cohort.
    Dong SJ; de las Fuentes L; Brown AL; Waggoner AD; Ewald GA; Dávila-Román VG
    J Am Soc Echocardiogr; 2006 Aug; 19(8):1017-25. PubMed ID: 16880097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials.
    McElwee JH; Gourdin TS; Mikoll J; Weeda E; Sion AM
    J Oncol Pharm Pract; 2020 Jun; 26(4):861-865. PubMed ID: 31566113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
    Bodnar L; Kopczyńska A; Żołnierek J; Wieczorek-Rutkowska M; Chrom P; Tomczak P
    Clin Genitourin Cancer; 2019 Jun; 17(3):e556-e564. PubMed ID: 30987807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
    Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
    ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
    Graham J; Ghosh S; Breau RH; Wood L; Tanguay S; Bosse D; Lalani AK; Bhindi B; Heng D; Finelli A; Fallah-Rad N; Castonguay V; Basappa NS; Soulières D; Pouliot F; Kollmannsberger C; Bjarnason GA
    Clin Genitourin Cancer; 2024 Jun; 22(3):102060. PubMed ID: 38521648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib improves clinical outcomes in renal cancer.
    Das M
    Lancet Oncol; 2017 Jan; 18(1):e2. PubMed ID: 27890466
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
    Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.
    Roviello G; Generali D
    Eur Urol; 2017 Dec; 72(6):1027-1028. PubMed ID: 28760645
    [No Abstract]   [Full Text] [Related]  

  • 20. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E; Jug B; Blagus R; Zakotnik B
    Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.